Saturday 17 October 2026
Export LIANY’s income statement to Excel — free account
LianBio Sponsored ADR
LIANY Healthcare Biotechnology
0.05
0.00
0.00%
Follow LIANY
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 5.86 | 1.07 | 1.33 | 0.24 | 0.03 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 16.37 | 6.48 | 4.78 | 4.99 | 0.44 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 87 | 107 | 163 | — | — | — | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | (24) | (140) | (196) | (111) | 311 | 2 | 5 | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (24) | (140) | (196) | (110) | 311 | 2 | 5 | |||||
| Depreciation | — | — | — | — | 0 | 1 | 1 | 1 | 1 | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (0.22) | (11.58) | (5.71) | (1.02) | 2.89 | 0.02 | 0.04 | |||||
| Cash flow | — | — | — | (0.11) | (8.14) | (4.77) | (0.92) | 2.40 | 0.03 | 0.05 | |||||
| Capex | — | — | — | 0.00 | (0.07) | (0.03) | (0.02) | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (0.11) | (8.22) | (4.79) | (0.94) | 2.40 | 0.03 | 0.05 | |||||
| Book value | — | — | — | 0.36 | (8.14) | 11.26 | 2.72 | 5.39 | 0.58 | 0.19 | |||||
| Shares, m | — | — | — | 108 | 12 | 34 | 108 | 108 | 108 | 109 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (12) | (98) | (164) | (99) | 259 | 4 | 5 | ||||
| Capex | — | — | — | — | (1) | (1) | (2) | 0 | — | — | |||||
| Free cash flow | — | — | — | (12) | (99) | (165) | (101) | 259 | 4 | 5 | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 40 | 271 | 385 | 289 | 577 | 63 | 21 | ||||
| Total debt | — | — | — | 1 | 2 | 5 | 4 | — | — | — | |||||
| Net debt | — | — | — | (43) | (254) | (383) | (302) | (567) | (52) | (9) | |||||
| Shareholders’ equity | — | — | — | 39 | (98) | 387 | 294 | 581 | 63 | 21 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (111.09) | (86.40) | (55.64) | (29.56) | 66.19 | 0.73 | 11.63 | ||||
| ROIC | — | — | — | 0.00 | 0.00 | (2,990.73) | 0.00 | (450.47) | (217.43) | (7.12) | |||||
| ROE | — | — | — | 32.79 | 245.17 | (135.72) | (32.39) | 70.96 | 0.77 | 11.75 | |||||
Negative figures in brackets.
Charts ten years each
LianBio Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| EDSA Edesa Biotech, Inc. | $36.1M | — (loss-making) | — (loss-making) | −99.88% (below 0%: shrinking) | n/m | −81.24% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NNVC NanoViricides, Inc. | $35.0M | — (loss-making) | — | — | n/m | −23.94% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LIANY LianBio Sponsored ADR | $34.2M | 0.0× | — | — | n/m | +1,107.59% (above 0%: growing) | 0.00% | 0.00% | |
| CRVO CervoMed Inc. | $34.0M | — (loss-making) | — (loss-making) | −99.60% (below 0%: shrinking) | n/m | −6.20% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IRLA Quince Therapeutics, Inc. | $33.8M | — (loss-making) | — | — | n/m | −63.65% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALGS Aligos Therapeutics, Inc. | $33.7M | — (loss-making) | — (loss-making) | +2,778.55% (above 0%: growing) | n/m | −59.81% (below 0%: shrinking) | 100.00% | (6.80%) | Compare |
| ATNM Actinium Pharmaceuticals, Inc. | $33.3M | 3.1× | — (loss-making) | +77,677.78% (above 0%: growing) | n/m | −4.91% (below 0%: shrinking) | 100.00% | 78.76% | Compare |
| BCTX BRIACELL THERAP | $32.8M | 1.5× | — | — | n/m | +0.21% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GNTA Genenta Science S.p.A. Unsponsored ADR | $32.3M | — | — | — | — | +35.94% (above 0%: growing) | 0.00% | — | Compare |
| Median of peers | $33.7M | — | — | +1,339.48% | — | −15.07% | 0.00% | 0.00% |
LianBio Sponsored ADR (LIANY) key facts
- LianBio Sponsored ADR (LIANY) is a Biotechnology company in the Healthcare sector.
- As of October 16, 2026, LIANY traded at $0.05, a market capitalization of $34.2 million.
- Return on equity was 11.8% and debt-to-equity 0.00.